Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.